SEARCH

SEARCH BY CITATION

References

  • 1
    Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance—Astrup revisited. Haemostasis 1999; 0: 5871.
  • 2
    Bachmann F. Plasminogen–plasmin enzyme system. In: ColmanRW, HirshJ, MarderVJ, ClowesAW, GeorgeJN, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 275320.
  • 3
    Schatteman K, Goossens F, Leurs J, Verkerk R, Scharpe S, Michiels JJ, Hendriks D. Carboxypeptidase U at the interface between coagulation and fibrinolysis. Clin Appl Thromb Hemost 2001; 7: 93101.
  • 4
    Castellino FJ. Plasminogen. In: HighKA, RobertsHR, eds. Molecular Basis of Thrombosis and Hemostasis. New York: Marcel Dekker, 1995: 495515.
  • 5
    Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 2907.
  • 6
    Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87115.
  • 7
    Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 826.
  • 8
    Berrettini M, Schleef RR, Espana F, Loskutoff DJ, Griffin JH. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989; 264: 1173843.
  • 9
    Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 1302935.
  • 10
    Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 125461.
  • 11
    Urano T, Ihara H, Takada Y, Nagai N, Takada A. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. Biochim Biophys Acta 1996; 1298: 199208.
  • 12
    Urano T, Ihara H, Suzuki Y, Nagai N, Takada Y, Takada A. Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism. Fibrinolysis Proteolysis 1999; 13: 26471.
  • 13
    Urano T, Ihara H, Takada Y, Fujie M, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme. Blood Coagul Fibrinolysis 2000; 11: 14553.
  • 14
    Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 34960.
  • 15
    Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 121823.
  • 16
    Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093100.
  • 17
    Kojima Y, Urano T, Kojima K, Serizawa K, Takada Y, Takada A. The significant enhancement of fibrinolysis by calcium ion in a cell free system: the shortening of euglobulin clot lysis time by calcium ion. Thromb Haemost 1994; 72: 1138.
  • 18
    Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1990; 63: 4853.
  • 19
    Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 98592.
  • 20
    Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66: 4748.
  • 21
    Bakker HM, Tans G, Janssen-Claessen T, Thomassen MC, Hemker HC, Griffin JH, Rosing J. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208: 1718.
  • 22
    Jenny NS, Mann KG. Thrombin. In: ColmanRE, HirshJ, MarderVJ, ClowesAW, GeorgeJN, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincot Williams & Wilkins, 2001: 17190.
  • 23
    Malhotra OP, Chang HY, Koehler KA. The pH-dependence of the equilibrium between the fast- and slow-folding forms of bovine prothrombin fragment 1: a role for pH-induced self association? Biochem Biophys Res Commun 1995; 206: 7427.
  • 24
    Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991; 115: 177381.
  • 25
    Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 1993; 268: 1236772.
  • 26
    Kost C, Benner K, Stockmann A, Linder D, Preissner KT. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996; 236: 6828.
  • 27
    Urano T, De Serrano VS, Urano S, Castellino FJ. Stimulation by fibrinogen of the amidolytic activity of single-chain tissue plasminogen activator. Arch Biochem Biophys 1989; 270: 35662.
  • 28
    Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80: 1616.
  • 29
    Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, Hashimoto K, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86: 105661.
  • 30
    Urano T, Ihara H, Umemura K, Suzuki Y, Oike M, Akita S, Tsukamoto Y, Suzuki I, Takada A. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001; 276: 246906.
  • 31
    De Fouw NJ, De Jong YF, Haverkate F, Bertina RM. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor—no evidence for a cofactor role of protein S. Thromb Haemost 1988; 60: 32833.
  • 32
    Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 1556770.
  • 33
    Taylor FB Jr, Hoogendoorn H, Chang AC, Peer G, Nesheim ME, Catlett R, Stump DC, Giles AR. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood 1992; 79: 17208.
  • 34
    Castellino FJ. Gene targeting in hemostasis: protein C. Front Biosci 2001; 6: D80719.
  • 35
    Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 94451.
  • 36
    Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, Takeda N, Ito M, Yamamoto K, Matsushita T, Kusugami K, Muramatsu T, Saito H. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 8738.
  • 37
    Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest 1998; 101: 66776.